Early effect of simultaneous intravitreal dexamethasone and bevacizumab combination treatment in patients with persistent diabetic macular edema
Journal Français d'Ophtalmologie, ISSN: 0181-5512, Vol: 44, Issue: 6, Page: 849-854
2021
- 5Citations
- 9Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations5
- Citation Indexes5
- CrossRef1
- Captures9
- Readers9
Article Description
To report the early effect of simultaneous intravitreal dexamethasone and bevacizumab combination treatment in patients with persistent diabetic macular edema (DME). In this single-center prospective non-randomized study, 65 eyes of 59 patients with persistent DME were included. In the combined group (Group 1), we treated 35 eyes of 29 persistent DME patients with a simultaneous combination of intravitreal dexamethasone and bevacizumab, and in the control group (Group 2), we treated 30 eyes of 30 patients with intravitreal bevacizumab. Changes in Best Corrected Visual Acuity (BCVA), Central Macular Thickness (CMT) and Intraocular Pressure (IOP) from the initial visit to each subsequent follow-up visit (1st, 2nd and 3rd months) were recorded. In Group 1, the mean baseline Early Treatment Diabetic Retinopathy (ETDRS) BCVA letter score was 44.1 ± 19.3 (range 20–51), improving significantly to 58.8 ± 18.2 (range 42–73) in the first month ( P < 0.05), 57 ± 19.2 (range 40–72) in the second month ( P < 0.05) and 55.4 ± 18.4 (range 34–71) in the third month ( P < 0.05). In Group 2, the mean pre-injection BCVA ETDRS letter score was 43.3 ± 18.8 (range 20–56) and did not improve significantly; the letter score was 44.3 ± 18.1 (range 20–49) in the third month. In Group 1, the mean BCVA change from baseline to the 3rd month was 11.3 ETDRS letters. In Group 2, the mean BCVA change from baseline to the 3rd month was 1 ETDRS letter. In Group 1, the mean reduction in CMT from baseline was −142.25 μm. In Group 2, the mean reduction in CMT from baseline was −17.30 μm. In Group 1 at the third month, 12 (34.2%) eyes with a CMT > 300 μm needed an additional injection. No serious ocular or systemic side effects occurred in any patient. Simultaneous intravitreal dexamethasone and bevacizumab combination treatment is effective and can be used safely in persistent DME. Evaluer l’effet précoce du traitement combiné simultané à la dexaméthasone et au bévacizumab chez les patients présentant un œdème maculaire diabétique persistant (DME). Dans cette étude prospective monocentrique non randomisée, 65 yeux de 59 patients souffrant de DME persistant ont été inclus. Dans le groupe combiné (groupe 1), nous avons traité 35 yeux de 29 patients avec DME persistant avec une combinaison de dexaméthasone et de bévacizumab et dans le groupe témoin (groupe 2), nous avons traité 30 yeux de 30 patients avec le bévacizumab seul. La meilleure acuité visuelle corrigée (BCVA), l’épaisseur maculaire centrale (CMT) et la pression intraoculaire (PIO) depuis la visite initiale et à chaque visite de suivi (lors du1 er, 2 e et 3 e mois) ont été enregistrés. Dans le groupe 1, les BCVA étaient de 44,1 ± 19,3 (intervalle 20–51) et se sont améliorées de manière significative à 58,8 ± 18,2 (intervalle 42–73) le premier mois ( p < 0,05), à 57 ± 19,2 (intervalle 40–72) au deuxième mois ( p < 0,05) et à 55,4 ± 18,4 (intervalle 34–71) au troisième mois ( p < 0,05). Dans le groupe 2, le score moyen en ETDRS pré-injection était de 43,3 ± 18,8 (20–56) et ne s’est pas amélioré de manière significative, soit 44,3 ± 18,1 (20–49) au cours du troisième mois. Dans le premier groupe, le changement moyen d’acuité visuelle au 3 e mois était de 11,3 lettres ETDRS. Dans le groupe 1, la réduction moyenne de la CMT par rapport à la valeur initiale était de −142,25 μm. Dans le groupe 2, la réduction moyenne de la CMT par rapport à la ligne de base était de −17,30 μm. Dans le groupe 1, au troisième mois, 12 yeux (34,2 %) avaient de nouveau besoin d’une injection avec CMT > 300 μm. Aucun effet secondaire grave oculaire ou systémique n’est survenu chez aucun patient. Le traitement combiné à la dexaméthasone et au bévacizumab est efficace et peut être utilisé en toute sécurité dans les DME persistants.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0181551221001911; http://dx.doi.org/10.1016/j.jfo.2020.08.033; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85103933702&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/33840497; https://linkinghub.elsevier.com/retrieve/pii/S0181551221001911; https://dx.doi.org/10.1016/j.jfo.2020.08.033
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know